GlassScriptPhysician profile
Rosa Marquez
NPI 1114524378
$2,513.28
in general payments reported to CMS, 2019-2025
15 companies · $741 in 2025
The $741 reported for 2025 was more than what 86% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.86 · 2022: $427 · 2023: $608 · 2024: $662 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.72 |
| Education | $126.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,018.47 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $325.38 | 2022-2025 | |
| Janssen Biotech, INC. | $279.21 | 2023-2025 | Tremfya |
| Ucb, INC. | $190.17 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $152.85 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $113.03 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $102.44 | 2022-2025 | Lupkynis |
| Radius Health, INC. | $82.22 | 2023-2025 | Tymlos |
| Pfizer INC. | $80.15 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $54.61 | 2024-2025 | Idacio |
| Sandoz INC. | $31.56 | 2024 | Hyrimoz |
| Horizon Therapeutics Plc | $26.00 | 2023 | |
| Glaxosmithkline, LLC. | $24.34 | 2021-2023 | Benlysta |
| Si-Bone, INC. | $20.06 | 2022 | |
| Genentech USA, INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.